Cargando…

Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments

BACKGROUND AND OBJECTIVE: Doravirine is currently not recommended for pregnant women living with human immunodeficiency virus because efficacy and safety data are lacking. This study aimed to predict maternal and fetal doravirine exposure by integrating human placenta perfusion experiments with preg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bukkems, V. E., van Hove, H., Roelofsen, D., Freriksen, J. J. M., van Ewijk-Beneken Kolmer, E. W. J., Burger, D. M., van Drongelen, J., Svensson, E. M., Greupink, R., Colbers, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349081/ https://www.ncbi.nlm.nih.gov/pubmed/35579825 http://dx.doi.org/10.1007/s40262-022-01127-0

Ejemplares similares

Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically‐Based Pharmacokinetic Modeling
por: Freriksen, Jolien J.M., et al.
Publicado: (2020)

Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling
por: Schalkwijk, Stein, et al.
Publicado: (2017)

Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta
por: Eliesen, Gaby A. M., et al.
Publicado: (2020)

Review article: direct‐acting antivirals for the treatment of HCV during pregnancy and lactation ‐ implications for maternal dosing, foetal exposure, and safety for mother and child
por: Freriksen, Jolien J. M., et al.
Publicado: (2019)

A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV
por: Bukkems, Vera E., et al.
Publicado: (2021)

Highly sensitive quantification of pemetrexed in human plasma using UPLC‐MS/MS to support microdosing studies
por: van Ewijk‐Beneken Kolmer, Eleonora W. J., et al.
Publicado: (2021)

Non‐clinical considerations for supporting accelerated inclusion of pregnant women in pre‐licensure clinical trials with anti‐HIV agents
por: Greupink, Rick, et al.
Publicado: (2022)

Social Workers’ Orientation Toward the Evidence-Based Practice Process: A Dutch Survey
por: van der Zwet, Renske J. M., et al.
Publicado: (2014)

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients
por: te Brake, Lindsey H.M., et al.
Publicado: (2018)

Partitioning of glutamine synthesised by the isolated perfused human placenta between the maternal and fetal circulations()
por: Day, P.E.L., et al.
Publicado: (2013)

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps
por: van der Galiën, Ruben, et al.
Publicado: (2018)

Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
por: Bukkems, Vera E., et al.
Publicado: (2020)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
por: Colbers, Angela, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population
por: Freriksen, Jolien J. M., et al.
Publicado: (2022)

Quality of Life: The Interplay between Human Behaviour, Technology and the Environment
por: van Hoof, Joost, et al.
Publicado: (2019)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Changes in weight and BMI with first-line doravirine-based therapy
por: Orkin, Chloe, et al.
Publicado: (2021)

Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling
por: Jacobs, Tom G., et al.
Publicado: (2023)

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
por: Rock, Alexander E, et al.
Publicado: (2020)

Impact of reduced uterine perfusion pressure model of preeclampsia on metabolism of placenta, maternal and fetal hearts
por: McClements, Lana, et al.
Publicado: (2022)

Low raltegravir transfer into the breastmilk of a woman living with HIV
por: Feiterna-Sperling, Cornelia, et al.
Publicado: (2020)

Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
por: Martin, Elizabeth Anne, et al.
Publicado: (2020)

Perfusion and apparent oxygenation in the human placenta (PERFOX)
por: Hutter, Jana, et al.
Publicado: (2019)

Shuni Virus Replicates at the Maternal-Fetal Interface of the Ovine and Human Placenta
por: Oymans, Judith, et al.
Publicado: (2020)

Phenylalanine transfer across the isolated perfused human placenta: an experimental and modeling investigation
por: Lofthouse, E. M., et al.
Publicado: (2015)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model
por: Zizioli, Daniela, et al.
Publicado: (2023)

‘Fetal side’ of the placenta: anatomical mis-annotation of carbon particle ‘transfer’ across the human placenta
por: Holder, Beth, et al.
Publicado: (2021)

Ambient black carbon particles reach the fetal side of human placenta
por: Bové, Hannelore, et al.
Publicado: (2019)

Transfer and Metabolism of Cortisol by the Isolated Perfused Human Placenta
por: Stirrat, Laura I., et al.
Publicado: (2017)

Toxicity of anticancer drugs in human placental tissue explants and trophoblast cell lines
por: Eliesen, Gaby A. M., et al.
Publicado: (2020)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
por: Molina, Jean-Michel, et al.
Publicado: (2022)

Multipotent fetal-derived Cdx2 cells from placenta regenerate the heart
por: Vadakke-Madathil, Sangeetha, et al.
Publicado: (2019)

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2023)

Feasibility of a Pragmatic PBPK Modeling Approach: Towards Model-Informed Dosing in Pediatric Clinical Care
por: van der Heijden, Joyce E. M., et al.
Publicado: (2022)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Placenta accreta spectrum ultrasound stage and fetal growth
por: Bartels, Helena C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u1pis4o0roluj8q5pr6q0jfnue